- Research article
- Open Access
The influence of dietary peptide inhibitors of angiotensin-converting enzyme on the hypotensive effects of enalapril
© Watanabe et al.; licensee BioMed Central. 2015
- Received: 21 January 2015
- Accepted: 15 May 2015
- Published: 3 June 2015
Enalapril is an antihypertensive medicine that inhibits angiotensin I-converting enzyme (ACE). The present study investigated interactions between enalapril and a fermented milk product (FMP) containing the ACE-inhibitory peptides, Val-Pro-Pro (VPP) and Ile-Pro-Pro (IPP).
Single-dose and long-term (6-week) in vivo studies were used to investigate the effects of enalapril and FMP on blood pressure in spontaneously hypertensive rats.
Single-dose oral administration of concomitant enalapril and FMP (VPP, IPP: 3.5 mg/kg) produced a lower antihypertensive effect than enalapril monotherapy. However, this effect was not observed in animals administered a lower dose of FMP (VPP, IPP: 1.75 mg/kg) along with enalapril. In rats administered enalapril concomitantly with a fish protein product (FPP) containing a different ACE inhibitory peptide (Leu-Lys-Pro-Asn-Met), significant attenuation of the antihypertensive effect was also observed 1 and 2 h after administration, as compared to enalapril monotherapy. During a 6-week oral administration study, the enalapril monotherapy group showed significant antihypertensive effects compared to those observed in the controls on day 28. Oral administration of enalapril and FMP, with a 1-h interval between doses, resulted in significant antihypertensive effects on day 35, indicating a delayed onset in comparison to enalapril monotherapy. In rats receiving enalapril monotherapy for 28 days, followed by 14 days of concomitant FMP, significant antihypertensive effects were observed after day 35, and these did not differ significantly from the effects observed during enalapril monotherapy.
The present findings suggested that long-term concomitant intake of FMP and enalapril could influence the antihypertensive effects of this drug.
- Drug interaction
- Fermented milk
- Angiotensin I-converting enzyme inhibitor
- Concomitant administration
- Foods for specified health uses
Foods for Specified Health Uses (FOSHU) have been approved by the Japanese Ministry of Health, Labour and Welfare after demonstrating tangible benefits. FOSHU may contain biologically active ingredients with a range of activities, such as decreasing blood pressure or cholesterol levels. These provide prophylaxis for lifestyle-related diseases, such as hypertension, diabetes, obesity, osteoporosis, and cardiovascular disease . At present, many FOSHU such as tea, beverages, gum, etc. are available over-the-counter and have been widely adopted in everyday life.
Hypertension can be treated using lifestyle measures, such as increasing physical activity, maintaining a normal body weight, and adopting a healthy diet. In addition, borderline hypertensive subjects can ingest FOSHU containing peptide inhibitors of angiotensin I-converting enzyme (ACE). Several randomized trials and meta-analyses have shown that some peptides derived from milk proteins, such as Val-Pro-Pro (VPP) and Ile-Pro-Pro (IPP), decrease systolic blood pressure [2–4]. VPP and IPP, first isolated from milk fermented with Lactobacillus helveticus, show ACE-inhibitory activity and their antihypertensive effects have been studied extensively in spontaneously hypertensive rats (SHR) [5, 6], and in humans [7, 8]. At present, a fermented milk product (FMP) containing these peptides is commercially available in Japan (trade name, Ameel S®) and this FOSHU is readily available to people, irrespective of whether they are taking other antihypertensive medications.
There are few published studies on the effects of combined intake of FMP and a prescribed ACE inhibitor. The present study therefore investigated the hypotensive effects of concomitant use of FMP and an ACE inhibitor, enalapril. Because antihypertensive drugs are commonly administered continuously over a long period, this study investigated long-term administration of FMP and enalapril. An initial investigation of concomitant oral administration of enalapril and either FMP or a commercially available fish protein product (FPP; trade name, Peptide Straight®) containing a bioactive peptide (Leu-Lys-Pro-Asn-Met; LKPNM) was carried out . We then conducted a long-term oral administration study to model a situation where patients took concomitant FOSHU and enalapril, and the other scenario where patients already taking oral antihypertensive medication started to take FOSHU. SHR therefore received daily oral concomitant enalapril and FMP for 6 weeks, or enalapril monotherapy for 28 days, followed by concomitant FMP for a further 14 days.
This study was performed in accordance with the guidelines for animal experimentation of Teikyo University. Male SHR rats were purchased from the Sankyo Laboratory Service Corporation (Tokyo, Japan) and then underwent a 4-week preliminary observation at 22-24 °C, 55 % humidity, with 12 h of lighting (0800–2000) and food and water ad libitum. Thirteen-week-old rats (body weight: 250–290 g) were used for the single administration study and 15-week-old rats (body weight: 235–270 g) were used for the long-term administration study.
One Ameel S Handy Tab® (CALPIS Co. Ltd., Tokyo, Japan), labeled as containing 1.7 mg of VPP and IPP in total, was crushed and dissolved in distilled water to give a total volume of either 2.9 mL (for dosing at 3.5 mg/kg ) or 5.8 mL (for dosing at 1.75 mg/kg). In the enalapril monotherapy group, 0.5 mg/mL enalapril maleate (Wako Junyaku Inc., Tokyo, Japan) solution was prepared using distilled water. For concomitant enalapril and FMP administration, 1 Ameel S Handy Tab® was crushed and added to a 1.0 mg/mL enalapril solution to give a total volume of 2.9 mL. In the FPP monotherapy group, one bag containing 1.9 g of Peptide Straight® (Japan Supplement Foods Co. Ltd., Osaka City, Japan; 4.75 mg LKPNM) was crushed and dissolved in distilled water to obtain a total volume of 3.5 mL. In the concomitant FPP and enalapril group, 1.9 g Peptide Straight® was crushed and added to a 0.4 mg/mL enalapril solution to give a total volume of 3.5 mL. The control group was orally administered 6 mL/kg distilled water.
Test product administration
Three types of single administration studies were conducted using the following 4 groups (n = 4 rats per group): Study 1, (I) control (distilled water), (II) enalapril (3 mg/kg) monotherapy, (III) FMP (VPP, IPP: 3.5 mg/kg), and (IV) concomitant enalapril (3 mg/kg) and FMP (VPP, IPP: 3.5 mg/kg); Study 2, (I) control (distilled water), (II) enalapril (3 mg/kg) monotherapy, (III) FMP (VPP, IPP: 1.75 mg/kg), and (IV) concomitant enalapril (3 mg/kg) and FMP (VPP, IPP: 1.75 mg/kg); and Study 3, (I) control (distilled water), (II) enalapril (3 mg/kg) monotherapy; (III) FPP (LKPNM; 10 mg/kg LKPNM .), and (IV) concomitant enalapril (3 mg/kg) and FPP (LKPNM; 10 mg/kg LKPNM). These doses of FMP and enalapril were based on the human doses of 5–10 mg enalapril daily and 3.4 mg VPP/IPP in FMP. The test products were administered orally using a nasogastric tube (KN-349, Natsume, Tokyo, Japan) at the scheduled time (1000–1145). In the long-term administration study, rats received each preparation separately, with an interval of 1 h between the first and second administration. This study was conducted using the following groups and dosing schedules (n = 5 rats per group): (I) control (distilled water, followed by distilled water); (II) enalapril monotherapy (distilled water, followed by 3 mg/kg enalapril); (III) concomitant enalapril and FMP (VPP, IPP: 3.5 mg/kg), followed by 3 mg/kg enalapril); and (IV) delayed combination (distilled water, followed by 3 mg/kg enalapril for 28 days, switching to FMP [VPP, IPP: 3.5 mg/kg], followed by 3 mg/kg enalapril for a further 14 days). During the 6-week study period, administration took place daily at scheduled times (first administration: 1130–1200; second administration: 1230–1300).
Blood pressure measurement
Systolic blood pressure was measured by the tail cuff method using the Non-Preheating, Non-Invasive Blood Pressure Monitor for Mice and Rats (MK-2000, Muromachi Kikai, Tokyo, Japan). Blood pressure measurements were performed 5–10 times consecutively when the rat was at rest. During the single administration study, blood pressure was measured immediately before administration and at 1, 2, 4, and 6 h after administration. During the long-term administration study, systolic blood pressure was measured immediately before the start of administration and prior to oral dosing on days 3, 7, 10, 14, 17, 21, 24, 28, 31, 35, 38, and 42 (after day 42, no test product was administered). This study schedule was based on a previous report .
A change in the hypertensive state was calculated as a percentage of systolic blood pressure measured immediately before the start of administration.
The mean blood pressure value was used for analysis. Values were expressed as the mean ± standard error of the mean (SE). After one-way analysis of variance, the Bonferroni/Dunn or Scheffe multiple comparison test was performed.
Single administration study
Meanwhile, intestinal absorption of the highly hydrophobic VPP seems to occur via a paracellular pathway involving tight junctions, rather than involving a peptide transporter . Furthermore, the FMP effects disappeared when a lower concentration was employed, perhaps indicating a dose-dependent effect or involvement of a saturable transporter. In addition, intestinal peptide transporters (PEPT1 and PEPT2) exhibit high affinity for endogenous peptides but it was not the case occasionally. It may be probable that VPP exhibits very low affinity to be saturated in such concentration range. Therefore, further investigation is required to evaluate FMP pharmacokinetics and to elucidate the mechanism of the observed interaction with enalapril.
Long-term administration study
When enalapril monotherapy was supplemented by FMP, significant antihypertensive effects were observed on days 35 and 42 (both p < 0.05) in the delayed combination group. Moreover, these effects were not significantly different from those observed during enalapril monotherapy (Fig. 2). This suggested that FMP administration had no effect on ongoing enalapril treatment. This may relate to the finding by many studies that FMP (or VPP/IPP) only exert their effects in subjects with clinically established hypertension [7, 19–23].
Many previous reports have shown that the long-term intake of FMP, or IPP and VPP tripeptides, effectively lowers blood pressure in SHR [10, 24] and humans [7, 8, 19–22, 25–27]. However, this is the first report of a potential interaction between an ACE inhibitor and a FOSHU product containing ACE inhibitory peptides in SHR with long-term administration.
The present findings suggested that long-term concomitant intake of FMP and enalapril could influence the antihypertensive effects of this drug. Therefore, they may be beneficial to people who have health concerns about taking ACE inhibitors over extended periods of time.
- Arai S, Osawa T, Ohigashi H, Yoshikawa M, Kaminogawa S, Watanabe M, et al. A mainstay of functional food science in Japan-history, present status, and future outlook. Biosci Biotechnol Biochem. 2001;65:1–13.PubMedView ArticleGoogle Scholar
- Pripp AH. Effect of peptides derived from food proteins on blood pressure: a meta-analysis of randomized controlled trials. Food Nutr Res. 2008;52.Google Scholar
- Xu JY, Qin LQ, Wang PY, Li W, Chang C. Effect of milk tripeptides on blood pressure: a meta-analysis of randomized controlled trials. Nutrition. 2008;24:933–40.PubMedView ArticleGoogle Scholar
- Cicero AF, Gerocarni B, Laghi L, Borghi C. Blood pressure lowering effect of lactotripeptides assumed as functional foods: a meta-analysis of current available clinical trials. J Hum Hypertens. 2011;25:425–36.PubMedView ArticleGoogle Scholar
- Nakamura Y, Yamamoto N, Sakai K, Takano T. Antihypertensive effect of sour milk and peptides isolated from it that are inhibitors to angiotensin I-converting enzyme. J Dairy Sci. 1995;78:1253–7.PubMedView ArticleGoogle Scholar
- Nakamura Y, Yamamoto N, Sakai K, Okubo A, Yamazakim S, Takano T. Purification and characterization of angiotensin I-converting enzyme inhibitors from sour milk. J Dairy Sci. 1995;78:777–83.PubMedView ArticleGoogle Scholar
- Hata Y, Yamamoto M, Ohni M, Nakajima K, Nakamura Y, Takano T. A placebo-controlled study of the effect of sour milk on blood pressure in hypertensive subjects. Am J Clin Nutr. 1996;64:767–71.PubMedGoogle Scholar
- Aihara K, Kajimoto O, Hirata H, Takahashi R, Nakamura Y. Effect of powdered fermented milk with Lactobacillus helveticus on subjects with high-normal blood pressure or mild hypertension. J Am Coll Nutr. 2005;24:257–65.PubMedView ArticleGoogle Scholar
- Fujita H, Yoshikawa M. LKPNM: a prodrug-type ACE-inhibitory peptide derived from fish protein. Immunopharmacology. 1999;44:123–7.PubMedView ArticleGoogle Scholar
- Sipola M, Finckenberg P, Santisteban J, Korpela R, Vapaatalo H, Nurminen ML. Long-term intake of milk peptides attenuates development of hypertension in spontaneously hypertensive rats. J Physiol Pharmacol. 2001;52:745–54.PubMedGoogle Scholar
- Matsui T, Zhu XL, Watanabe K, Tanaka K, Kusano Y, Matsumoto K. Combined administration of captopril with an antihypertensive Val-Tyr di-peptide to spontaneously hypertensive rats attenuates the blood pressure lowering effect. Life Sci. 2006;79:2492–8.PubMedView ArticleGoogle Scholar
- Swaan PW, Stehouwer MC, Tukker JJ. Molecular mechanism for the relative binding affinity to the intestinal peptide carrier. Comparison of three ACE-inhibitors: enalapril, enalaprilat, and lisinopril. Biochim Biophys Acta. 1995;1236:31–8.PubMedView ArticleGoogle Scholar
- Knütter I, Wollesky C, Kottra G, Hahn MG, Fischer W, Zebisch K, et al. Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008;327:432–41.PubMedView ArticleGoogle Scholar
- Satake M, Enjoh M, Nakamura Y, Takano T, Kawamura Y, Arai S, et al. Transepithelial transport of the bioactive tripeptide, Val-Pro-Pro, in human intestinal Caco-2 cell monolayers. Biosci Biotechnol Biochem. 2002;66:378–84.PubMedView ArticleGoogle Scholar
- Hirota T, Nonaka A, Matsushita A, Uchida N, Ohki K, Asakura M, et al. Milk casein-derived tripeptides, VPP and IPP induced NO production in cultured endothelial cells and endothelium-dependent relaxation of isolated aortic rings. Heart Vessels. 2001;26:549–56.View ArticleGoogle Scholar
- Masuda O, Nakamura Y, Takano T. Antihypertensive peptides are present in aorta after oral administration of sour milk containing these peptides to spontaneously hypertensive rats. J Nutr. 1996;126:3063–8.PubMedGoogle Scholar
- Nakamura Y, Masuda O, Takano T. Decrease of tissue angiotensin I-converting enzyme activity upon feeding sour milk in spontaneously hypertensive rats. Biosci Biotechnol Biochem. 1996;60:488–9.PubMedView ArticleGoogle Scholar
- Pina AS, Roque AC. Studies on molecular recognition between bioactive peptides and angiotensin-converting enzyme. J Mol Recognit. 2009;22:162–8.PubMedView ArticleGoogle Scholar
- Jauhiainen T, Vapaatalo H, Poussa T, Kyrönpalo S, Rasmussen M, Korpela R. Lactobacillus helveticus fermented milk lowers blood pressure in hypertensive subjects in 24-h ambulatory blood pressure measurement. Am J Hypertens. 2005;18:1600–5.PubMedView ArticleGoogle Scholar
- Mizushima S, Ohshige K, Watanabe J, Kimura M, Kadowaki T, Nakamura Y, et al. Randomized controlled trial of sour milk on blood pressure in borderline hypertensive men. Am J Hypertens. 2004;17:701–6.PubMedView ArticleGoogle Scholar
- Seppo L, Jauhiainen T, Poussa T, Korpela R. A fermented milk high in bioactive peptides has a blood pressure-lowering effect in hypertensive subjects. Am J Clin Nutr. 2003;77:326–30.PubMedGoogle Scholar
- Tuomilehto J, Lindström J, Hyyrynen J, Korpela R, Karhunen M-L, Mikkola L, et al. Effect of ingesting sour milk fermented using Lactobacillus helveticus bacteria producing tripeptides on blood pressure in subjects with mild hypertension. J Hum Hypertens. 2004;18:795–802.PubMedView ArticleGoogle Scholar
- Engberink MF, Schouten EG, Kok FJ, van Mierlo LA, Brouwer IA, Geleijnse JM. Lactotripeptides show no effect on human blood pressure: results from a double-blind randomized controlled trial. Hypertension. 2008;51:399–405.PubMedView ArticleGoogle Scholar
- Sipola M, Finckenberg P, Korpela R, Vapaatalo H, Nurminen ML. Effect of long-term intake of milk products on blood pressure in hypertensive rats. J Dairy Res. 2002;69:103–11.PubMedView ArticleGoogle Scholar
- Mizuno S, Matsuura K, Gotou T, Nishimura S, Kajimoto O, Yabune M, et al. Antihypertensive effect of casein hydrolysate in a placebo-controlled study in subjects with high-normal blood pressure and mild hypertension. Br J Nutr. 2005;94:84–91.PubMedView ArticleGoogle Scholar
- Sano J, Ohki K, Higuchi T, Aihara K, Mizuno S, Kajimoto O, et al. Effect of casein hydrolysate, prepared with protease derived from Aspergillus oryzae, on subjects with high-normal blood pressure or mild hypertension. J Med Food. 2005;8:423–30.PubMedView ArticleGoogle Scholar
- Seppo L, Kerojoki O, Suomalainen T, Korpela R. The effect of Lactobacillus helveticus LBK-16 H fermented milk on hypertension - a pilot study on humans. Milchwissenschaft. 2002;57:124–7.Google Scholar
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.